Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aventis SA

Division of Sanofi
www.aventis.com

Latest From Aventis SA

Takeda/Shire Deal Stands Fifth Largest In Biopharma M&A

The $62.4bn price tag for Takeda’s acquisition of Shire is topped globally only by the Pfizer take-outs of Warner-Lambert and Wyeth, the merger that created GlaxoSmithKline, and Actavis’ purchase of Allergan.

Japan Europe

Payer Pushback Underpins Mallinckrodt's Disappointing Q3 Results

Mallinckrodt's high-priced H.P Acthar Gel was under pressure in the third quarter, which management attributed to payer complexities. The issue is broader than just Acthar, firm says.

Sales & Earnings Reimbursement

ESSA Pharma Will Fit Into Xtandi, Zytiga Prostate Cancer Treatment Gaps

Emerging Company Profile: ESSA Pharma, a publically traded cancer R&D company, believes it has the answer to drug resistance in patients treated with best-selling cancer therapies Xtandi and Zytiga – as it targets last-line patients with a prostate cancer therapy based on a new mechanism of action.

StartUps and SMEs Research & Development

Asia On The Move: Sanofi China GM Moves To Japan

The fall season ushers in a flurry of personnel changes at Sanofi, Amgen and Astellas.

BioPharmaceutical China
See All

Company Information

UsernamePublicRestriction

Register